Trial Profile
A Phase 1/2 Uncontrolled, Open Label Study Of Photodynamic Vaccination [verteporfin and detox-B adjuvant] In Patients With Stage III/IV Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Feb 2012
Price :
$35
*
At a glance
- Drugs Verteporfin (Primary) ; Detox B
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 18 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2005 New trial record.